1. A pharmaceutical composition for eliciting an immune response against tumor cells, comprising a) tumor cells that are apoptotic, wherein apoptosis is caused by treatment with high hydrostatic pressure, and b) dendritic cells. The pharmaceutical composition according to claim 1, characterized in that the tumor cells were subjected to hydrostatic pressure for at least 10 minutes under a pressure of at least 200 MPa. The pharmaceutical composition according to claim 1, characterized in that the tumor cells were treated with hydrostatic pressure from 10 minutes to 2 hours under a pressure of 200-250 MPa. A pharmaceutical composition according to any one of claims 1 to 3, characterized in that the apoptotic tumor cells are not necrotic. The pharmaceutical composition according to claims 1 to 3, characterized in that the tumor cells were taken from the tumor cell line. The pharmaceutical composition according to claims 1 to 3, characterized in that the tumor cells were taken from a tumor isolated from the body of the patient to be treated. The pharmaceutical composition according to claim 1, characterized in that the immature dendritic cells were loaded with apoptotic tumor cells treated with high hydrostatic pressure. The pharmaceutical composition according to claim 7, characterized in that the immature dendritic cells were obtained by leukapheresis. The pharmaceutical composition of claim 8, wherein the immature dendritic cells were obtained by leukapheresis and cultivation in vitro in the presence of cytokines. The pharmaceutical composition according to claim 1 for use in the treatment of patients suffering from cancer in the early as well as in the late stage1. Фармацевтическая композиция для вызывания иммунной реакции против опухолевых клеток, включающаяa) опухолевые клетки, являющиеся апоптотическими, причем апоптоз вызывается путем обработки высоким гидростатическим давлением, иb) дендритные клетки.2. Фармацевтическая композиция по п.1, отличающаяся тем, что о
